No Compromises, Native Molecule Drug Discovery Assays Using Mass Spectrometry

DATE

November 30, 2023

TIME

8:00 a.m. PST / 11:00 a.m. EST / 16:00 GMT / 17:00 CET - Duration: 60 Minutes

Overview

Recently there has been increased interest in screening chemical libraries for non-covalent or covalent binding to RNA or protein drug discovery targets using native conditions. Solution phase binding with native targets and test compounds avoids potential compromises inherent to assays based on labeled or immobilized components. In this webinar, we will describe simple, automated, and high throughput workflows utilizing mass spectrometry (MS) to measure drug candidate binding. Two workflows will be described in detail: 1) non-covalent/reversible binding by Affinity Selection Mass Spectrometry (ASMS) and 2) covalent/irreversible binding by intact mass shift assays.

Both methodologies facilitate the efficient interrogation of large data sets in a high-throughput manner followed by further hit candidate characterization. These MS-based assay methods are applicable to many different classes of targets and therapeutic areas, for example: RNA and protein degraders, RNA as a novel drug target, molecular glues and protein-protein interactions. Some of the advantages of this methodology over other drug target binding assay methods are minimal target quantity and assay development is required, protocol flexibility, target versatility, and primary hits are immediately identified and available for further confirmation and follow-up experiments (i.e., K_inact/K_i measurements, peptide mapping, quantitative proteomics, etc.).

Key Learning Objectives:

Understand how and when to use the ASMS & intact mass shift workflows for drug discovery screening
Learn about the advantages of native molecule mass spectrometry binding assays versus other methodologies
Learn how to utilize mass spectrometry for hit follow-up confirmation and characterization

Who Should Attend:

Scientists interested in drug discovery screening, especially binding assays
Pharma/Biopharma VPs, Directors, and team leaders looking to improve the success rate and speed to results of their drug discovery binding assays

Brought to you by:

Speakers

Can Ozbal
Founder & CEO,
Momentum Biotechnologies

William LaMarr
Senior VP Research & Development,
Momentum Biotechnologies

Melissa O'Meara
Forensic Science Consultant,
C&EN Media Group

Registration

Forwarded this event? Clear the form

Email Address*

Salutation

First Name*

Last Name*

Company*

Job Title*

Address 1*

City*

State*

Zip / Post Code*

Country*

Business Phone*

Does your organization currently utilize high throughput drug discovery screens?*

Does your organization utilize MS-based binding screens: ASMS, Intact Mass Shift (covalent binding) *

Are you interested in learning more about proteomics assays to qualify your targets, hits or leads?*

I would like to receive more information on products and services from the American Chemical Society

address2

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

View On Demand Webinars